{"schema_version":"secwatch.filing_event.v1","accession":"0000885590-26-000008","form_type":"8-K","ticker":"BHC","cik":"0000885590","company_name":"Bausch Health Companies Inc.","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.918018+00:00","generated_at":"2026-05-16T08:38:26.355509+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text","bullets":["Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.","Trial evaluated primary prevention of hepatic encephalopathy; specific endpoint outcomes not provided in filing summary.","Filing includes only the 8-K body; the attached Exhibit 99.1 text was not included for analysis.","Item 7.01 Regulation FD disclosure; information is furnished, not filed, per standard practice."],"urls":{"canonical":"https://secwatch.observer/filing/0000885590-26-000008","json":"https://secwatch.observer/filing/0000885590-26-000008.json","markdown":"https://secwatch.observer/filing/0000885590-26-000008.md","text":"https://secwatch.observer/filing/0000885590-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885590/000088559026000008/0000885590-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885590/000088559026000008/bhc-20260123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:38:26.355509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}